These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32353369)

  • 1. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
    Noureddin M; Chan JL; Barradas K; Dimick-Santos L; Schabel E; Omokaro SO; Anania FA; Myers RP; Miller V; Sanyal AJ; Chalasani N;
    Gastroenterology; 2020 Aug; 159(2):422-427.e1. PubMed ID: 32353369
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
    Cheung A; Neuschwander-Tetri BA; Kleiner DE; Schabel E; Rinella M; Harrison S; Ratziu V; Sanyal AJ; Loomba R; Jeannin Megnien S; Torstenson R; Miller V;
    Hepatology; 2019 Nov; 70(5):1841-1855. PubMed ID: 31034092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
    Ratziu V; Ghabril M; Romero-Gomez M; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):28-38. PubMed ID: 30300289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
    Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V;
    Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264
    [No Abstract]   [Full Text] [Related]  

  • 6. [Machanism and intervention of nonalcoholic steatohepatitis-associated fibrosis].
    Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):415-419. PubMed ID: 31357755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology guided treatment of nonalcoholic steatohepatitis.
    Nguyen TA; Sanyal AJ
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):58-64. PubMed ID: 22320918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
    Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
    Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.
    Yadav Y; Syn WK; Basu R
    Diabetes Technol Ther; 2019 Nov; 21(11):611-618. PubMed ID: 31335197
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor: Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Yao M; Lu F
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2697-2698. PubMed ID: 36403729
    [No Abstract]   [Full Text] [Related]  

  • 13. Perspectives on Treatment for Nonalcoholic Steatohepatitis.
    Lassailly G; Caiazzo R; Pattou F; Mathurin P
    Gastroenterology; 2016 Jun; 150(8):1835-48. PubMed ID: 26971824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
    Diehl AM; Day C
    N Engl J Med; 2017 Nov; 377(21):2063-2072. PubMed ID: 29166236
    [No Abstract]   [Full Text] [Related]  

  • 15. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease.
    Goodman ZD
    Clin Liver Dis; 2023 May; 27(2):353-362. PubMed ID: 37024212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
    Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
    Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Steatohepatitis.
    Suzuki A; Diehl AM
    Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study.
    Axley P; Ahmed Z; Arora S; Haas A; Kuo YF; Kamath PS; Singal AK
    Liver Transpl; 2019 May; 25(5):695-705. PubMed ID: 30861321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.